ClinicalTrials.gg
CompletedNCT04489888Updated Jun 19, 2025Results posted

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

A Phase 4 interventional study of Pembrolizumab and Carboplatin in Squamous Cell Carcinoma of Head and Neck, sponsored by Merck Sharp & Dohme LLC. Completed at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck — 18 open to participants now, 32 under way, 2 of them phase 3. pembrolizumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
17th of 63
101 · median 50
Started
2020
with 4 others
Phase 4
Only one
of the 63
Registered
33rd of 63
by date
Lead sponsor
4 of 63
Merck Sharp & Dohme LLC

Among the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 17th largest by enrollment, is one of 5 that started in 2020, is the only one in phase 4, and was the 33rd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

18 of the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 5 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically-confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies
  • Male participants refrain from donating sperm plus are abstinent from heterosexual intercourse or agree to use during the intervention period and for at least 95 days after carboplatin/paclitaxel
  • Female participants are not pregnant or breastfeeding and are either not a woman of (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or 30 days after paclitaxel or 6 months after carboplatin whichever occurs last, and agree not to donate or freeze eggs during this period
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has disease that is suitable for local therapy administered with curative intent
  • Has a of less than 3 months and/or has rapidly progressive disease
  • Has a diagnosed and/or treated additional within 5 years prior to allocation with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected in situ cervical cancer and curatively resected in situ breast cancer
  • Has received a live or within 30 days prior to the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior to the first dose of study intervention
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of or current non-infectious pneumonitis/interstitial lung disease that requires steroids
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of or virus infection
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Carboplatin + Paclitaxel

    Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to \~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to \~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m\^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to \~4 months) or at a dose of 175 mg/m\^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to \~4 months).

    Drug: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle

    Also known as: MK-3475, KEYTRUDA®

  • Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle

    Also known as: PARAPLATIN®

  • At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle

    Also known as: TAXOL®, ONXAL®

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per Response Evaluation Criteria in Solid Tumors Update and Clarification 1.1 (RECIST 1.1) which was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented.

    Time frame: Up to ~25 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first. RECIST 1.1 was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The DOR as assessed by blinded independent central review based on RECIST 1.1 was presented.

    Time frame: Up to ~25 months

  2. Progression-free Survival (PFS)

    PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. RECIST 1.1 was been adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to ~25 months

  3. Overall Survival (OS)

    OS was defined as the time from first dose of study treatment to death due to any cause. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to ~25 months

  4. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE was reported.

    Time frame: Up to ~39 months

  5. Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to ~25 months

07

Results

Posted May 9, 2024

Participant flow

101 participants were enrolled in the All Participants as Treated (APaT) population. The APaT population consisted of all allocated participants who received at least one dose of study intervention.

Participant flow — Overall Study
MilestonePembrolizumab + Carboplatin + Paclitaxel
Started101
Completed0
Not completed101
Withdrew: Death75
Withdrew: Sponsor decision26

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per Response Evaluation Criteria in Solid Tumors Update and Clarification 1.1 (RECIST 1.1) which was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented.

Time frame:
Up to ~25 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsPembrolizumab + Carboplatin + Paclitaxel
Objective Response Rate (ORR)48.5 (38.4 to 58.7)
SecondaryDuration of Response (DOR)

For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first. RECIST 1.1 was adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The DOR as assessed by blinded independent central review based on RECIST 1.1 was presented.

Time frame:
Up to ~25 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + Carboplatin + Paclitaxel
Duration of Response (DOR)5.5 (4.2 to 6.7)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. RECIST 1.1 was been adjusted for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to ~25 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsPembrolizumab + Carboplatin + Paclitaxel
Progression-free Survival (PFS)5.6 (5.1 to 6.7)
SecondaryOverall Survival (OS)

OS was defined as the time from first dose of study treatment to death due to any cause. PFS as assessed by blinded independent central review based on RECIST 1.1 was from product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to ~25 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + Carboplatin + Paclitaxel
Overall Survival (OS)13.1 (9.6 to 15.2)
SecondaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE was reported.

Time frame:
Up to ~39 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of participantsPembrolizumab + Carboplatin + Paclitaxel
Percentage of Participants Who Experienced an Adverse Event (AE)100.0
SecondaryPercentage of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to ~25 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Percentage of ParticipantsPembrolizumab + Carboplatin + Paclitaxel
Percentage of Participants Who Discontinued Study Treatment Due to an AE36.6

Adverse events

Collected over Up to approximately 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Carboplatin + Paclitaxel75/101 (74.3%)52/101 (51.5%)100/101 (99%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPembrolizumab + Carboplatin + Paclitaxel
PneumoniaInfections and infestations12/101
Febrile neutropeniaBlood and lymphatic system disorders6/101
Pneumonia aspirationInfections and infestations6/101
Neutrophil count decreasedInvestigations5/101
SepsisInfections and infestations4/101
AnaemiaBlood and lymphatic system disorders3/101
DehydrationMetabolism and nutrition disorders3/101
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/101
Acute kidney injuryRenal and urinary disorders3/101
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/101
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPembrolizumab + Carboplatin + Paclitaxel
Neutrophil count decreasedInvestigations57/101
AnaemiaBlood and lymphatic system disorders47/101
FatigueGeneral disorders47/101
ConstipationGastrointestinal disorders40/101
NauseaGastrointestinal disorders36/101
AlopeciaSkin and subcutaneous tissue disorders35/101
White blood cell count decreasedInvestigations34/101
DiarrhoeaGastrointestinal disorders32/101
Platelet count decreasedInvestigations32/101
Lymphocyte count decreasedInvestigations25/101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Carboplatin + Paclitaxel
Mean63.8 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Carboplatin + Paclitaxel
Female16
Male85
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Carboplatin + Paclitaxel
Hispanic or Latino43
Not Hispanic or Latino58
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Carboplatin + Paclitaxel
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White88
More than one race7
Unknown or Not Reported0
08

Study locations

35 sites
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0265)
    New Haven, Connecticut 06510, United States
  • Helen F. Graham Cancer Center & Research Institute ( Site 0214)
    Newark, Delaware 19718, United States
  • Baptist MD Anderson Cancer Center ( Site 0215)
    Jacksonville, Florida 32207, United States
  • Orlando Health, Inc. ( Site 0216)
    Orlando, Florida 32806, United States
  • Regions Hospital ( Site 0227)
    Saint Paul, Minnesota 55101, United States
  • Washington University School of Medicine ( Site 0240)
    Saint Louis, Missouri 63110, United States
  • Erie County Medical Center-Head & Neck Surgery and Plastic & Reconstructive Surgery ( Site 0268)
    Buffalo, New York 14215, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0262)
    Mineola, New York 11501, United States
  • Novant Health Presbyterian ( Site 0261)
    Charlotte, North Carolina 28204, United States
  • Novant Health Forsyth Medical Center ( Site 0266)
    Winston-Salem, North Carolina 27103, United States
  • UPMC Hillman Cancer Center ( Site 0253)
    Pittsburgh, Pennsylvania 15232, United States
  • Abington Hospital - Asplundh Cancer Center ( Site 0229)
    Willow Grove, Pennsylvania 19090, United States
  • Charleston Oncology ( Site 0231)
    Charleston, South Carolina 29414, United States
  • Virginia Commonwealth University ( Site 0233)
    Richmond, Virginia 23219, United States
  • Hospital Provincial del Centenario ( Site 0304)
    Rosario, Santa Fe 2000, Argentina
  • Centro Medico San Roque ( Site 0302)
    San Miguel de Tucuman, Tucuman T4000IAK, Argentina
  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0303)
    Buenos Aires, C1012AAR, Argentina
  • Fundación Respirar ( Site 0306)
    Buenos Aires, C1426ABP, Argentina
  • Instituto Medico Especializado Alexander Fleming ( Site 0301)
    Buenos Aires, C1426ANZ, Argentina
  • Orange Health Services ( Site 0106)
    Orange, New South Wales 2800, Australia
  • The Townsville Hospital ( Site 0105)
    Douglas, Queensland 4814, Australia
  • Gold Coast University Hospital ( Site 0103)
    Southport, Queensland 4215, Australia
  • St Vincents Hospital Melbourne ( Site 0101)
    Fitzroy, Victoria 3065, Australia
  • Centro Regional Integrado de Oncologia ( Site 0403)
    Fortaleza, Ceara 60336-232, Brazil
  • CETUS Hospital Dia Oncologia ( Site 0400)
    Belo Horizonte, Minas Gerais 30110-022, Brazil
  • Liga Norte Riograndense Contra o Cancer ( Site 0404)
    Natal, Rio Grande Do Norte 59075-740, Brazil
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0406)
    Ijui, Rio Grande Do Sul 98700-000, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0402)
    Sao Paulo, 01246-000, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0401)
    Sao Paulo, 01321-001, Brazil
  • A.C. Camargo Cancer Center ( Site 0405)
    Sao Paulo, 01509-900, Brazil
  • Tom Baker Cancer Center ( Site 0014)
    Calgary, Alberta T2N 4N2, Canada
  • Dr. H. Bliss Murphy Cancer Centre ( Site 0001)
    Saint John S, Newfoundland and Labrador A1B 3V6, Canada
  • Cancer Centre of Southeastern Ontario at Kingston General Hospital ( Site 0004)
    Kingston, Ontario K7L 2V7, Canada
  • Princess Margaret Cancer Centre ( Site 0005)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0003)
    Sherbrooke, Quebec J1H 5N4, Canada
09

References and documents

Publications

  • Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. J Clin Oncol. 2024 Sep 1;42(25):2989-2999. doi: 10.1200/JCO.23.02625. Epub 2024 Jul 22. PubMed 39038265 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Feb 2023, 27 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 28, 2020
StartActual
Oct 27, 2020
Primary completionActual
Feb 20, 2023
CompletionActual
Jun 28, 2024
Results first posted
May 9, 2024
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04489888
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Oct 27, 2020
Primary completion
Feb 20, 2023
Completion
Jun 28, 2024
Results posted
May 9, 2024
Last update
Jun 19, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion